The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study.

WILMINGTON, Del., June 01, 2025--Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of ...

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to results from a phase 3 study. Adding Imfinzi to the chemotherapy regimen ...

Imfinzi remains a key revenue driver for AstraZeneca’s oncology portfolio. In the first quarter of 2025, Imfinzi generated sales of $1.26 billion, up 16%, driven by demand growth in lung and ...

Imfinzi has been approved in the US and other countries for the same indication based on the NIAGARA results, with regulatory applications under review in Japan and several other countries.

With sales of its lone product in a precipitous decline in the United States, Amarin has turned to an experienced local ...

Imfinzi recommended in EU for bladder cancer | Regulatory News ...

AstraZeneca said patients treated with the Imfinzi-based regimen before, during and after surgery had a 29% reduction in the risk of disease progression, recurrence or death compared to ...

Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI ® (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin ...

IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial Business Wire Jun 1, 2025 ...